74 results
8-K
EX-99.1
SYRE
Spyre Therapeutics Inc.
9 May 24
Spyre Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:11pm
of maximizing efficacy, safety, and convenience of its IBD treatments under development. IBD is a chronic condition characterized by inflammation within
POS AM
SYRE
Spyre Therapeutics Inc.
26 Mar 24
Prospectus update (post-effective amendment)
6:30pm
-negative patients (e.g., false-negatives) are not unduly burdened with access restrictions.
Inflammatory Bowel Disease
IBD is a chronic condition
POS AM
SYRE
Spyre Therapeutics Inc.
14 Mar 24
Prospectus update (post-effective amendment)
4:12pm
is a chronic condition characterized by inflammation within the gastrointestinal tract. It encompasses two main disorders: UC and CD. UC primarily affects
POS AM
7fv9 z27du
5 Mar 24
Prospectus update (post-effective amendment)
5:15pm
8-K
EX-99.1
i3zo0 q6ts03
29 Feb 24
Spyre Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
4:14pm
8-K
EX-99.1
snvyx j671i37ul
9 Nov 23
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:06pm
PRER14A
79duf
6 Oct 23
Preliminary revised proxy
9:40pm
8-K
EX-99.1
0ni5lh
8 Sep 23
Material Modifications to Rights of Security Holders
5:05pm
8-K
EX-99.1
m74q12eb 9aizl
11 Aug 23
Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results
7:02am